There is 1 version of this bill. View text

Click the check-box to add or remove the section, click the text link to scroll to that section.
Titles Actions Overview All Actions Cosponsors Committees Related Bills Subjects Latest Summary All Summaries

Titles (3)

Short Titles

Short Titles - Senate

Short Titles as Introduced

Fair AMP Act
Fair and Accurate Medicaid Pricing Act of 2019

Official Titles

Official Titles - Senate

Official Titles as Introduced

A bill to amend title XIX of the Social Security Act to exclude authorized generic drugs from calculation of the average manufacturer price for purposes of the Medicaid drug rebate program, and for other purposes.

Actions Overview (1)

06/11/2019Introduced in Senate

All Actions (1)

06/11/2019Read twice and referred to the Committee on Finance.
Action By: Senate

Cosponsors (5)

* = Original cosponsor
CosponsorDate Cosponsored
Sen. Cassidy, Bill [R-LA]* 06/11/2019
Sen. Stabenow, Debbie [D-MI]* 06/11/2019
Sen. Cornyn, John [R-TX]* 06/11/2019
Sen. Cardin, Benjamin L. [D-MD]* 06/11/2019
Sen. Young, Todd [R-IN]* 06/11/2019

Committees (1)

Committees, subcommittees and links to reports associated with this bill are listed here, as well as the nature and date of committee activity and Congressional report number.

Committee / Subcommittee Date Activity Reports
Senate Finance06/11/2019 Referred to

A related bill may be a companion measure, an identical bill, a procedurally-related measure, or one with text similarities. Bill relationships are identified by the House, the Senate, or CRS, and refer only to same-congress measures.

Subjects (7)

Latest Summary (1)

There is one summary for S.1785. View summaries

Shown Here:
Introduced in Senate (06/11/2019)

Fair and Accurate Medicaid Pricing Act of 2019 or the Fair AMP Act

This bill alters certain requirements and definitions under the Medicaid Drug Rebate Program relating to rebate calculations. Specifically, the bill repeals the requirement that drug manufacturers include the prices of certain authorized generic drugs when determining the average manufacturer price (AMP) of brand-name drugs (also known as a "blended AMP"), and excludes manufacturers from the definition of "wholesalers" for purposes of rebate calculations.